China and US regulators share cancer drug approval experiences

As the trade war between the USA and China instigated by US President Donald Trump accelerates, at least the two countries’ healthcare regulators are still talking in a collaborative fashion.

Earlier this week, Xu Jinghe, Deputy Commissioner of the National Drug Administration of China (CNDA), attended the China US Exchange for Cancer Drug Development and Evaluation held jointly by CNDA and the US Food and Drug Administration.

The CNDA Center for Drug Evaluation (CDE) introduced the priority review of China's new anti-tumor drugs, and the US FDA Oncology Center of Excellence (OCE) has introduced the regulatory work of FDA in the novel anti-cancer drugs, expediting product development, listing and approving.